Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o
A phase 2/3 trial of FAP-2286 in colorectal cancer and ovarian cancer, run by GE Healthcare, now recruiting.
Overview
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) is a phase 2/3 interventional study registered as NCT07219238 by GE Healthcare, with 175 participants planned, started 2026-10 and due to reach its primary completion in 2029-06. Interventions recorded: GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT). Conditions listed: Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Shares FAP-2286 (177Lu / 68Ga), Gallium-68.
- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Shares FAP-2286 (177Lu / 68Ga), Gallium-68.
- TrialA Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Shares FAP-2286 (177Lu / 68Ga), Gallium-68.
- IdeaFAP-targeted radioligand therapy for sarcoma
Shares FAP-2286 (177Lu / 68Ga), Gallium-68.
- AgentGallium-68 FAPI-46
Shares GE HealthCare, Gallium-68.
- OpportunityFAP imaging to stop futile pancreatic surgery
Shares FAP-2286 (177Lu / 68Ga), Gallium-68.
- AgentIobenguane I-123
Shares GE HealthCare, Gallium-68.
- PersonUwe Haberkorn
Shares FAP-2286 (177Lu / 68Ga), Gallium-68.